MedPlus Health Services Limited: history, ownership, mission, how it works & makes money

Born in Hyderabad in 2006 and originally trading as Aushadhi, MedPlus Health Services has grown into a nationwide healthcare chain that went public in December 2021 after raising ₹13,982.95 million via its IPO and now runs a network of 4,712 stores across India (adding 398 stores in the latest fiscal), combining traditional retail with diagnostics and digital services; the company reported revenue of ₹474.32 crore and a net profit of ₹51 crore in 2024, supports a workforce of 25,007 employees, operates 12 diagnostic centers and over 100 sample collection centers, and leverages ePharmacy, wholesale cash-and-carry, private-label manufacturing and a cluster-based expansion strategy-backed by a paid-up equity capital of ₹23.96 crore (11,969,383 shares) and an IPO structure that included a fresh issue of 7,544,511 shares for ₹6,000 million plus an offer for sale of 10,028,831 shares for ₹7,982.95 million-to position itself as India's second-largest pharmacy chain while targeting further store additions and digital service scale-up.

MedPlus Health Services Limited (MEDPLUS.NS): Intro

• Founded: 2006 by Madhukar Gangadi in Hyderabad; originally branded Aushadhi, rebranded to MedPlus after opening 48 stores.
• Service expansion: Launched online clinical laboratory services in 2015 to complement retail pharmacy offerings.
• IPO: Went public in December 2021, raising ₹13,982.95 million via a combination of fresh issue and offer for sale of equity shares.
• Store footprint (Mar 31, 2025): 4,712 stores nationwide; net addition of 398 stores in the fiscal year.
• Corporate action: In 2025 received NCLT approval for merger of wholly owned subsidiary MHS Pharmaceuticals Private Limited into MedPlus Health Services.

• Retail pharmacy network: Brick-and-mortar stores form the primary revenue engine-prescription medicines, OTC products, personal care and FMCG allied to healthcare.
• Omnichannel presence: In-store sales complemented by e-pharmacy and digital ordering, integrating inventory and last-mile delivery to capture online demand.
• Diagnostics & clinical labs: Launched online clinical laboratory services in 2015, providing tests and sample collection through store networks and tie-ups, increasing customer stickiness and per-customer revenue.
• Wholesale & distribution: B2B supply to smaller pharmacies and institutions leveraging scale purchasing, warehousing and distribution capabilities.
• Private label & MHS Pharmaceuticals: Manufacture/supply of in-house generic formulations and branded generics through subsidiary MHS Pharmaceuticals (merger approved 2025), improving margins and control over product mix.
• Value-added services: Health checks, chronic disease management programs, loyalty/subscription offers and cross-sell of allied healthcare products.

• Retail sales (prescription + OTC): Largest single revenue contributor driven by high-frequency purchases and recurring prescriptions.
• Online orders & app/website: Incremental sales channel with delivery fees, convenience premiums, and higher basket sizes for repeat users.
• Diagnostics services: Revenue from lab tests, sample collection fees and partnerships with diagnostic brands.
• Wholesale distribution: Margin on bulk sales to other retailers, clinics and hospitals.
• Private-label margins: Higher gross margins from MHS Pharmaceuticals products as integration completes post-merger.
• Value-added subscriptions / chronic care programs: Recurring revenue from membership and adherence services.

• Store expansion to increase geographic penetration and same-store sales uplift from ancillary services (diagnostics, chronic care).
• Integration of MHS Pharmaceuticals to source private-label products and improve gross margins.
• Scaling digital commerce and logistics to capture rising e-pharmacy demand while optimizing fulfilment economics.
• Cross-selling diagnostics and preventive health to raise per-customer lifetime value.

MedPlus Health Services Limited (MEDPLUS.NS): History

• Listed on BSE (543427) and NSE (MEDPLUS).
• Paid-up equity share capital: ₹23.96 crore (11,969,383 equity shares of ₹2 each) as of March 31, 2025.
• Employees: 25,007 as of March 31, 2025.

• Leadership: Managing Director & CEO G. Madhukar Reddy; CFO Sujit Mahato; COO Cherukupalli Reddy.
• Board: Includes G. Madhukar Reddy, Sujit Mahato, Cherukupalli Reddy and other directors responsible for strategy and governance.

• Retail network: Large chain of company-owned and operated pharmacies serving walk-in customers and prescriptions.
• Distribution & logistics: Centralized warehouses and last-mile distribution to ensure availability and inventory turns.
• Omnichannel: E-commerce platform and in-store pickup/ delivery integration to capture online demand.
• Diagnostics & services: In-store diagnostic tie-ups and value-added services to increase basket size and footfall.

MedPlus Health Services Limited (MEDPLUS.NS): Ownership Structure

• Mission: Deliver affordable, accessible healthcare and improve customer well‑being across urban and semi‑urban India.
• Core values: Customer‑centricity, innovation, integrity, community engagement, sustainability.
• Key service lines: Retail pharmacy stores, e-pharmacy and home delivery, clinical diagnostics (online lab services), and allied healthcare products.

• How MedPlus makes money:
  • Retail pharmacy sales (prescription and OTC medicines) - majority of revenue.
  • E‑commerce pharmacy and last‑mile delivery - growing share via omni‑channel model.
  • Clinical diagnostics and lab services - testing revenue and referral income since 2015.
  • Sale of FMCG and consumer healthcare products in stores.
  • Supply‑chain & wholesale services to smaller pharmacies in specific regions.
• Operational strengths:
  • High SKU availability and private label/product margin levers.
  • Integrated logistics and regional distribution centers to control costs and improve fulfillment.
  • Digital ordering and prescription management to increase frequency and retention.

MedPlus Health Services Limited (MEDPLUS.NS): Mission and Values

• Retail pharmacy network: Over 4,700 stores across urban, semi-urban and rural markets offering prescription medicines, over-the-counter (OTC) drugs, vitamins, personal care and FMCG products, and optical services.
• Diagnostics and lab services: A network of diagnostic centers and sample-collection points that extend clinical laboratory testing and pathology services alongside the retail footprint to provide a one-stop healthcare access point.
• ePharmacy and digital health: An online pharmacy platform and digital clinical-lab ordering that enable home delivery of medicines, tele-consultation tie-ups, and online booking for diagnostic tests, addressing growing consumer preference for digital healthcare channels.
• Wholesale cash & carry: Distribution operations that supply pharmacies, clinics and hospitals with pharmaceutical and wellness products through bulk sales to trade customers.
• Private-label manufacturing and trade: Development, manufacture and distribution of in-house pharmaceutical and wellness brands and FMCG items to improve margins, ensure quality consistency and lower dependence on third-party SKUs.
• Cluster-based expansion strategy: Focus on concentrated growth-deepening presence in existing strong markets (to gain share, optimize logistics and advertising) and then replicating the successful cluster model in adjacent regions.

• Retail sales: Margin on prescription and OTC medicines, FMCG and optical sales in stores-primary revenue driver from high-frequency consumer purchases.
• Diagnostics: Fee-for-service revenue from lab tests and diagnostic packages booked through centers and online.
• ePharmacy delivery fees and basket margins: Online order fulfillment margins, subscription or service fees where applicable, and higher average order values for repeat customers.
• Wholesale distribution: Bulk sales to retailers and institutional buyers at lower margin but high volume.
• Private-label margin capture: Higher gross margins on in-house brands by controlling manufacturing and supply chain.
• Value-added services: Optical services, health screenings, and allied services driving ancillary revenue and store traffic.

• Network effects: Large store base and distribution footprint enable better negotiating power with suppliers and faster roll-out of private-label SKUs.
• Cross-selling: Co-located diagnostics and retail create capture opportunities for health-seeking consumers (medicine fills post-tests, preventive product sales).
• Data-driven inventory: Cluster strategy allows centralized procurement, optimized inventory turns, and lower stockouts-improving service levels and reducing working capital.
• Digital integration: ePharmacy plus lab-booking platforms increase customer lifetime value (repeat ordering, subscription) and provide data for targeted promotions.

• Third-party logistics and local distributors for last-mile fulfilment; centralized distribution hubs serve multiple stores in a cluster to reduce lead times.
• Clinical labs and diagnostic technology partners to scale test offerings and quality assurance.
• Technology and payment partners to streamline ePharmacy checkouts, subscription models and digital records.

MedPlus Health Services Limited (MEDPLUS.NS): How It Works

• Retail pharmacy sales (prescription and OTC medicines, FMCG, nutraceuticals, personal care)
• Diagnostic services (lab tests, sample collection, partner networks)
• Digital platforms (ePharmacy, online lab booking and reports, mobile app)
• Wholesale cash-and-carry supply to independent retailers, clinics and hospitals
• Private-label manufacturing and trading of pharma, wellness and FMCG SKUs
• Store expansion and franchise/owned-store mix to scale reach and same-store sales

• Retail pharmacies sell medicines and high-margin front-end FMCG and wellness products; prescriptions drive repeat footfall and basket size.
• Diagnostics add per-test margins and cross-sell opportunities (medicines post-diagnosis).
• ePharmacy extends reach beyond store geographies, enabling subscription/repeat ordering and lower marginal fulfillment costs.
• Wholesale/cash-and-carry supplies benefit from bulk pricing and distribution efficiencies.
• Private-label products capture higher gross margins and improve shelf economics while reinforcing brand loyalty.
• New store openings increase market share, contribute incremental revenue, and dilute fixed costs when scaled.

• Prescription medicines: typically lower gross margin but high volume and repeat sales.
• Front-end FMCG & wellness: higher gross margins, impulse purchases, improves overall basket GP%.
• Diagnostics: moderate-to-high margin per test and recurring utilization by chronic patients.
• Private-label: highest margin uplift due to manufacturing control and branding.
• Wholesale: thinner margins per unit but scale and cash turnover advantages.

• Fixed costs (store lease, staff) are amortized as store revenues scale; multi-format presence improves utilization of logistics and procurement.
• Central buying and hydrogenated supply chain relationships lower COGS and improve inventory turns.
• Cross-sell from diagnostics to retail and from digital to stores raises customer lifetime value and reduces acquisition cost.

• Prescription visit → medicine sale at store or online (primary revenue).
• Diagnostic test ordered → lab revenue + post-test medicine/supplement sales.
• Repeat online orders / subscriptions → recurring revenue, lower fulfillment cost.
• Private-label purchase → higher margin captured on sale.

• Rapid store roll-out in underserved cities and towns to capture prescription demand.
• Scaling ePharmacy and telehealth tie-ins to increase digital share and retention.
• Expanding diagnostics footprint and home sample collection to increase per-customer revenue.
• Enhancing private-label portfolio to push margin-accretive sales.
• Wholesale distribution expansion to monetize procurement scale through B2B channels.

MedPlus Health Services Limited (MEDPLUS.NS): How It Makes Money

• Core retail pharmacy: prescription and over‑the‑counter medication sales across a large store network (over 4,700 stores across 600 cities as of 2024).
• Consumer healthcare & FMCG: fast‑moving healthcare products, personal care and wellness items sold in-store and online.
• Diagnostics & clinical lab services: revenue from diagnostics performed at owned centers and sample collection centers (12 diagnostic centers and >100 sample collection centers as of March 31, 2025).
• ePharmacy & digital offerings: online prescriptions, home delivery, teleconsultation tie‑ups and online lab test bookings driving incremental sales and lower acquisition costs.
• Private label and higher‑margin product mix: in-house brands and promoted SKUs to improve gross margins.

• Second‑largest pharmacy chain in India - scale advantage for vendor terms, inventory turns and store economics.
• Store expansion: ongoing rollout (398 additions in FY25) to deepen retail penetration and capture prescription continuity.
• Digital integration: omnichannel model reduces last‑mile cost and captures online healthcare demand (ePharmacy + online lab services).
• Service diversification: diagnostics and sample collection increase customer lifetime value and cross‑sell opportunities.
• Sustainability & CSR: initiatives to support long‑term brand trust and regulatory goodwill.